The FDA has accepted Lipocine’s Investigational New Drug Application (IND) for its neuroactive steroid (NAS) candidate, LPCN 2101, as a potential treatment for adults with epilepsy.
Lipocine now intends to start a Phase II photosensitive epilepsy study, to evaluate the safety, tolerability, and efficacy of oral LPCN 2101.
